Definition, Classification, and Pathophysiology of Canine Glaucoma

Veterinary Clinics of North America - Small Animal Practice

Volumn 45, Issue 6, 2015, Pages 1127-1157

  Pizzirani, Stefano ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

Canine; Closed angle; Glaucoma; Goniodysgenesis; Open angle; Primary glaucoma; Secondary glaucoma

Indexed keywords

GLUTAMIC ACID;

AGE; AQUEOUS HUMOR OUTFLOW; BIOMICROSCOPY; CILIARY CLEFT; CLINICAL EVALUATION; CLOSED ANGLE GLAUCOMA; CONGENITAL GLAUCOMA; DISEASE CLASSIFICATION; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOG BREED; DOG DISEASE; EYE; FAMILY HISTORY; GLAUCOMA; GONIOSCOPY; HUMAN; IRIDOCORNEAL ANGLE; LAMINA CRIBROSA; NONHUMAN; OPEN ANGLE GLAUCOMA; OXIDATIVE STRESS; PATHOGENESIS; PRIMARY GLAUCOMA; RETINA DEGENERATION; RETINA GANGLION CELL; REVIEW; RISK FACTOR; SCORING SYSTEM; SEX DIFFERENCE; THEORY; TRABECULAR MESHWORK; VISUAL SYSTEM PARAMETERS; AGING; ANIMAL; DOG; GENETIC PREDISPOSITION; GENETICS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; VETERINARY;

AGING; ANIMALS; DOG DISEASES; DOGS; GENETIC PREDISPOSITION TO DISEASE; GLAUCOMA; HUMANS;

EID: 84943384304     PISSN: 01955616     EISSN: 18781306     Source Type: Journal    
DOI: 10.1016/j.cvsm.2015.06.002     Document Type: Review

References (181)

1. Hernandez M.R. The optic nerve head in glaucoma: role of astrocytes in tissue remodeling. Prog Retin Eye Res 2000, 19(3):297-321.
2. Gupta V., You Y., Li J., et al. BDNF impairment is associated with age-related changes in the inner retina and exacerbates experimental glaucoma. Biochim Biophys Acta 2014, 1842(9):1567-1578.
3. Gordon M.O., Beiser J.A., Brandt J.D., et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002, 120(6):714-720. [discussion: 829-30].
4. Leske M.C., Heijl A., Hussein M., et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2003, 121(1):48-56.
5. Van Veldhuisen P.C., Ederer F., Gaasterland D.E., et al. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000, 130(4):429-440.
6. Brusini P., Johnson C.A. Staging functional damage in glaucoma: review of different classification methods. Surv Ophthalmol 2007, 52(2):156-179.
7. Klein B.E., Klein R., Sponsel W.E., et al. Prevalence of glaucoma. The Beaver Dam Eye Study. Ophthalmology 1992, 99(10):1499-1504.
8. Plummer C.E., Regnier A., Gelatt K.N. The canine glaucomas. Veterinary ophthalmology 2013, vol. 2:1050-1145. John Wiley, Inc, Ames (IA). 5th edition.
9. Ofri R., Dawson W.W., Foli K., et al. Primary open-angle glaucoma alters retinal recovery from a thiobarbiturate: spatial frequency dependence. Exp Eye Res 1993, 56(4):481-488.
10. Ofri R., Samuelson D.A., Strubbe D.T., et al. Altered retinal recovery and optic nerve fiber loss in primary open-angle glaucoma in the beagle. Exp Eye Res 1994, 58(2):245-248.
11. Gelatt K.N., Miyabayashi T., Gelatt-Nicholson K.J., et al. Progressive changes in ophthalmic blood velocities in Beagles with primary open angle glaucoma. Vet Ophthalmol 2003, 6(1):77-84.
12. Kallberg M.E., Brooks D.E., Gelatt K.N., et al. Endothelin-1, nitric oxide, and glutamate in the normal and glaucomatous dog eye. Vet Ophthalmol 2007, 10(Suppl 1):46-52.
13. Quigley H.A., Broman A.T. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006, 90(3):262-267.
14. Tektas O.Y., Lutjen-Drecoll E. Structural changes of the trabecular meshwork in different kinds of glaucoma. Exp Eye Res 2009, 88(4):769-775.
15. Pizzirani S., Desai S.J., Pirie C.G., et al. Age related changes in the anterior segment of the eye in normal dogs. Vet Ophthalmol 2010, 13(6):421.
16. Tian B., Geiger B., Epstein D.L., et al. Cytoskeletal involvement in the regulation of aqueous humor outflow. Invest Ophthalmol Vis Sci 2000, 41(3):619-623.
17. Alvarado J., Murphy C., Juster R. Trabecular meshwork cellularity in primary open-angle glaucoma and nonglaucomatous normals. Ophthalmology 1984, 91(6):564-579.
18. Grierson I., Hogg P. The proliferative and migratory activities of trabecular meshwork cells. Prog Retin Eye Res 1995, 15(1):33-67.
19. Babizhayev M.A., Brodskaya M.W. Fibronectin detection in drainage outflow system of human eyes in ageing and progression of open-angle glaucoma. Mech Ageing Dev 1989, 47(2):145-157.
20. Lutjen-Drecoll E. Morphological changes in glaucomatous eyes and the role of TGFbeta2 for the pathogenesis of the disease. Exp Eye Res 2005, 81(1):1-4.
21. Becker B. The decline in aqueous secretion and outflow facility with age. Am J Ophthalmol 1958, 46(5 Part 1):731-736.
22. Ekesten B., Torrang I. Age-related changes in ocular distances in normal eyes of Samoyeds. Am J Vet Res 1995, 56(1):127-133.
23. Tarongoy P., Ho C.L., Walton D.S. Angle-closure glaucoma: the role of the lens in the pathogenesis, prevention, and treatment. Surv Ophthalmol 2009, 54(2):211-225.
24. Rudnicka A.R., Mt-Isa S., Owen C.G., et al. Variations in primary open-angle glaucoma prevalence by age, gender, and race: a Bayesian meta-analysis. Invest Ophthalmol Vis Sci 2006, 47(10):4254-4261.
25. Alsbirk P.H. Anterior chamber depth in Greenland Eskimos. I. A population study of variation with age and sex. Acta Ophthalmol 1974, 52(4):551-564.
26. Gelatt K.N., MacKay E.O. Prevalence of the breed-related glaucomas in pure-bred dogs in North America. Vet Ophthalmol 2004, 7(2):97-111.
27. Tsai S., Almazan A., Lee S.S., et al. The effect of topical latanoprost on anterior segment anatomic relationships in normal dogs. Vet Ophthalmol 2013, 16(5):370-376.
28. Slater M.R., Erb H.N. Effects of risk factors and prophylactic treatment on primary glaucoma in the dog. J Am Vet Med Assoc 1986, 188(9):1028-1030.
29. Whitacre C.C. Sex differences in autoimmune disease. Nat Immunol 2001, 2(9):777-780.
30. Fuse N. Genetic bases for glaucoma. Tohoku J Exp Med 2010, 221(1):1-10.
31. Kuchtey J., Olson L.M., Rinkoski T., et al. Mapping of the disease locus and identification of ADAMTS10 as a candidate gene in a canine model of primary open angle glaucoma. PLoS Genet 2011, 7(2):e1001306.
32. Fan B.J., Wiggs J.L. Glaucoma: genes, phenotypes, and new directions for therapy. J Clin Invest 2010, 120(9):3064-3072.
33. Komáromy A.M., Petersen-Jones S.M. Genetics of Canine Primary Glaucomas. Vet Clin Small Anim 2015, in press.
34. Ekesten B., Narfstrom K. Correlation of morphologic features of the iridocorneal angle to intraocular pressure in Samoyeds. Am J Vet Res 1991, 52(11):1875-1878.
35. Wood J.L., Lakhani K.H., Read R.A. Pectinate ligament dysplasia and glaucoma in Flat Coated Retrievers. II. Assessment of prevalence and heritability. Vet Ophthalmol 1998, 1(2-3):91-99.
36. Bjerkas E., Ekesten B., Farstad W. Pectinate ligament dysplasia and narrowing of the iridocorneal angle associated with glaucoma in the English Springer Spaniel. Vet Ophthalmol 2002, 5(1):49-54.
37. Bedford P.G. A gonioscopic study of the iridocorneal angle in the English and American breeds of Cocker Spaniel and the Basset Hound. J Small Anim Pract 1977, 18(10):631-642.
38. Pearce W.G., Mielke B.C., Kulak S.C., et al. Histopathology and molecular basis of iridogoniodysgenesis syndrome. Ophthalmic Genet 1999, 20(2):83-88.
39. Wyman M., Ketring K. Congenital glaucoma in the basset hound: a biologic model. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol 1976, 81(4 Pt 1):OP645-652.
40. van der Linde-Sipman J.S. Dysplasia of the pectinate ligament and primary glaucoma in the Bouvier des Flandres dog. Vet Pathol 1987, 24(3):201-206.
41. Dubin AJ, Bentley E, Buhr KA, et al. Evaluation and identification of risk factors for primary angle-closure glaucoma (PACG) in Bouvier des Flandres dogs. Paper presented at: 45th Annual Meeting of the American College of Veterinary Ophthalmologists. Ft Worth, TX, October 8-11, 2014.
42. Quigley H.A. The iris is a sponge: a cause of angle closure. Ophthalmology 2010, 117(1):1-2.
43. Pearl R., Gould D., Spiess B. Progression of pectinate ligament dysplasia over time in two populations of Flat-Coated Retrievers. Vet Ophthalmol 2015, 18(1):6-12.
44. Miller P.E., Bentley E. Clinical Signs and Diagnosis of the Canine Primary Glaucomas. Vet Clin Small Anim 2015, in press.
45. Kass M.A., Heuer D.K., Higginbotham E.J., et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002, 120(6):701-713. [discussion: 829-30].
46. Miller P.E., Schmidt G.M., Vainisi S.J., et al. The efficacy of topical prophylactic antiglaucoma therapy in primary closed angle glaucoma in dogs: a multicenter clinical trial. J Am Anim Hosp Assoc 2000, 36(5):431-438.
47. Smith R.S., Zabaleta A., Savinova O.V., et al. The mouse anterior chamber angle and trabecular meshwork develop without cell death. BMC Dev Biol 2001, 1:3.
48. Idrees F., Vaideanu D., Fraser S.G., et al. A review of anterior segment dysgeneses. Surv Ophthalmol 2006, 51(3):213-231.
49. Gould D.B., John S.W. Anterior segment dysgenesis and the developmental glaucomas are complex traits. Hum Mol Genet 2002, 11(10):1185-1193.
50. Kroeber M., Davis N., Holzmann S., et al. Reduced expression of Pax6 in lens and cornea of mutant mice leads to failure of chamber angle development and juvenile glaucoma. Hum Mol Genet 2010, 19(17):3332-3342.
51. Cvekl A., Tamm E.R. Anterior eye development and ocular mesenchyme: new insights from mouse models and human diseases. Bioessays 2004, 26(4):374-386.
52. Vasiliou V., Gonzalez F.J. Role of CYP1B1 in glaucoma. Annu Rev Pharmacol Toxicol 2008, 48:333-358.
53. Chang T.C., Summers C.G., Schimmenti L.A., et al. Axenfeld-Rieger syndrome: new perspectives. Br J Ophthalmol 2012, 96(3):318-322.
54. Mohanty K., Tanwar M., Dada R., et al. Screening of the LTBP2 gene in a north Indian population with primary congenital glaucoma. Mol Vis 2013, 19:78-84.
55. Hollander D.A., Sarfarazi M., Stoilov I., et al. Genotype and phenotype correlations in congenital glaucoma. Trans Am Ophthalmol Soc 2006, 104:183-195.
56. Kulak S.C., Kozlowski K., Semina E.V., et al. Mutation in the RIEG1 gene in patients with iridogoniodysgenesis syndrome. Hum Mol Genet 1998, 7(7):1113-1117.
57. Tumer Z., Bach-Holm D. Axenfeld-Rieger syndrome and spectrum of PITX2 and FOXC1 mutations. Eur J Hum Genet 2009, 17(12):1527-1539.
58. Pumphrey S. Canine Secondary Glaucomas. Vet Clin Small Anim 2015, in press.
59. Ahram D.F., Cook A.C., Kecova H., et al. Identification of genetic loci associated with primary angle-closure glaucoma in the basset hound. Mol Vis 2014, 20:497-510.
60. Bedford P.G. Gonioscopy in the dog. J Small Anim Pract 1977, 18(10):615-629.
61. Grozdanic S.D., Kecova H., Harper M.M., et al. Functional and structural changes in a canine model of hereditary primary angle-closure glaucoma. Invest Ophthalmol Vis Sci 2010, 51(1):255-263.
62. Shaffer R.N. Primary glaucomas. Gonioscopy, ophthalmoscopy and perimetry. Trans Am Acad Ophthalmol Otolaryngol 1960, 64:112-127.
63. Read R.A., Wood J.L., Lakhani K.H. Pectinate ligament dysplasia (PLD) and glaucoma in Flat Coated Retrievers. I. Objectives, technique and results of a PLD survey. Vet Ophthalmol 1998, 1(2-3):85-90.
64. Gelatt K.N., Peiffer R.L., Gwin R.M., et al. Glaucoma in the beagle. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol 1976, 81(4 Pt 1):OP636-OP644.
65. Song B.J., Caprioli J. New directions in the treatment of normal tension glaucoma. Indian J Ophthalmol 2014, 62(5):529-537.
66. Tripathi R.C., Tripathi B.J., Haggerty C. Drug-induced glaucomas: mechanism and management. Drug Saf 2003, 26(11):749-767.
67. Salmon J.F. Predisposing factors for chronic angle-closure glaucoma. Prog Retin Eye Res 1999, 18(1):121-132.
68. Johnson G.J., Foster P.J. Can we prevent angle-closure glaucoma?. Eye 2005, 19(10):1119-1124.
69. Miller PE, Bentley E, Diehl KA, et al. High resolution ultrasound imaging of the anterior segment of dogs with primary glaucoma prior to and following the topical application of 0.005% latanoprost. Paper presented at: 34th Annual Meeting of the American College of Veterinary Ophthalmologists. Coeur D'Alene, October 22-25, 2003.
70. Pizzirani S, Carroll V, Pirie CG, et al. Pathologic factors involved with the late onset of canine glaucoma associated with goniodysgenesis. Preliminary study. Paper presented at: ACVO 39th Annual Conference. Boston, October 15-18, 2008.
71. Reilly C.M., Morris R., Dubielzig R.R. Canine goniodysgenesis-related glaucoma: a morphologic review of 100 cases looking at inflammation and pigment dispersion. Vet Ophthalmol 2005, 8(4):253-258.
72. Sacca S.C., Pulliero A., Izzotti A. The dysfunction of the trabecular meshwork during glaucoma course. J Cell Physiol 2015, 230(3):510-525.
73. Grierson I., Howes R.C. Age-related depletion of the cell population in the human trabecular meshwork. Eye 1987, 1(Pt 2):204-210.
74. Finkel T., Holbrook N.J. Oxidants, oxidative stress and the biology of ageing. Nature 2000, 408(6809):239-247.
75. Yang X.J., Ge J., Zhuo Y.H. Role of mitochondria in the pathogenesis and treatment of glaucoma. Chin Med J 2013, 126(22):4358-4365.
76. Fuchshofer R., Tamm E.R. The role of TGF-beta in the pathogenesis of primary open-angle glaucoma. Cell Tissue Res 2012, 347(1):279-290.
77. Tripathi R.C., Chan W.F.A., Li J., et al. Trabecular cells express the TGF-beta2 gene and secrete the cytokine. Exp Eye Res 1994, 58(5):523-528.
78. Fuchshofer R., Yu A.H., Welge-Lussen U., et al. Bone morphogenetic protein-7 is an antagonist of transforming growth factor beta 2 in human trabecular meshwork cells. Invest Ophthalmol Vis Sci 2007, 48(2):715-726.
79. Maatta M., Tervahartiala T., Harju M., et al. Matrix metalloproteinases and their tissue inhibitors in aqueous humor of patients with primary open-angle glaucoma, exfoliation syndrome, and exfoliation glaucoma. J Glaucoma 2005, 14(1):64-69.
80. Alexander J.P., Samples J.R., Van Buskirk E.M., et al. Expression of matrix metalloproteinases and inhibitor by human trabecular meshwork. Invest Ophthalmol Vis Sci 1991, 32(1):172-180.
81. Samuelson D.A., Gum G.G., Gelatt K.N. Ultrastructural changes in the aqueous outflow apparatus of beagles with inherited glaucoma. Invest Ophthalmol Vis Sci 1989, 30(3):550-561.
82. Kuchtey J., Kuchtey R.W. The microfibril hypothesis of glaucoma: implications for treatment of elevated intraocular pressure. J Ocul Pharmacol Ther 2014, 30(2-3):170-180.
83. Flammer J., Mozaffarieh M. What is the present pathogenetic concept of glaucomatous optic neuropathy?. Surv Ophthalmol 2007, 52(Suppl 2):S162-173.
84. Quigley H.A., Nickells R.W., Kerrigan L.A., et al. Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest Ophthalmol Vis Sci 1995, 36(5):774-786.
85. Garcia-Valenzuela E., Gorczyca W., Darzynkiewicz Z., et al. Apoptosis in adult retinal ganglion cells after axotomy. J Neurobiol 1994, 25(4):431-438.
86. Cullen S.P., Henry C.M., Kearney C.J., et al. Fas/CD95-induced chemokines can serve as "find-me" signals for apoptotic cells. Mol Cell 2013, 49(6):1034-1048.
87. Davidovich P., Kearney C.J., Martin S.J. Inflammatory outcomes of apoptosis, necrosis and necroptosis. Biol Chem 2014, 395(10):1163-1171.
88. Burgoyne C.F. A biomechanical paradigm for axonal insult within the optic nerve head in aging and glaucoma. Exp Eye Res 2011, 93(2):120-132.
89. Brooks D.E., Komaromy A.M., Kallberg M.E. Comparative optic nerve physiology: implications for glaucoma, neuroprotection, and neuroregeneration. Vet Ophthalmol 1999, 2(1):13-25.
90. Almasieh M., Wilson A.M., Morquette B., et al. The molecular basis of retinal ganglion cell death in glaucoma. Prog Retin Eye Res 2012, 31(2):152-181.
91. Johnson J.E., Barde Y.A., Schwab M., et al. Brain-derived neurotrophic factor supports the survival of cultured rat retinal ganglion cells. J Neurosci 1986, 6(10):3031-3038.
92. Mey J., Thanos S. Intravitreal injections of neurotrophic factors support the survival of axotomized retinal ganglion cells in adult rats in vivo. Brain Res 1993, 602(2):304-317.
93. Morgan J.E. Optic nerve head structure in glaucoma: astrocytes as mediators of axonal damage. Eye 2000, 14(Pt 3B):437-444.
94. Alyahya K., Chen C.T., Mangan B.G., et al. Microvessel loss, vascular damage and glutamate redistribution in the retinas of dogs with primary glaucoma. Vet Ophthalmol 2007, 10(Suppl 1):70-77.
95. Sacca S.C., Izzotti A., Rossi P., et al. Glaucomatous outflow pathway and oxidative stress. Exp Eye Res 2007, 84(3):389-399.
96. Izzotti A., Bagnis A., Sacca S.C. The role of oxidative stress in glaucoma. Mutat Res 2006, 612(2):105-114.
97. Chrysostomou V., Trounce I.A., Crowston J.G. Mechanisms of retinal ganglion cell injury in aging and glaucoma. Ophthalmic Res 2010, 44(3):173-178.
98. Yan D.B., Coloma F.M., Metheetrairut A., et al. Deformation of the lamina cribrosa by elevated intraocular pressure. Br J Ophthalmol 1994, 78(8):643-648.
99. Quigley H.A., Hohman R.M., Addicks E.M., et al. Morphologic changes in the lamina cribrosa correlated with neural loss in open-angle glaucoma. Am J Ophthalmol 1983, 95(5):673-691.
100. Flammer J., Orgul S., Costa V.P., et al. The impact of ocular blood flow in glaucoma. Prog Retin Eye Res 2002, 21(4):359-393.
101. Flammer J., Pache M., Resink T. Vasospasm, its role in the pathogenesis of diseases with particular reference to the eye. Prog Retin Eye Res 2001, 20(3):319-349.
102. Tezel G. Oxidative stress in glaucomatous neurodegeneration: mechanisms and consequences. Prog Retin Eye Res 2006, 25(5):490-513.
103. Bechetoille A., Bresson-Dumont H. Diurnal and nocturnal blood pressure drops in patients with focal ischemic glaucoma. Graefes Arch Clin Exp Ophthalmol 1994, 232(11):675-679.
104. Flammer J. The vascular concept of glaucoma. Surv Ophthalmol 1994, 38(Suppl):S3-6.
105. Gelatt-Nicholson K.J., Gelatt K.N., MacKay E.O., et al. Comparative Doppler imaging of the ophthalmic vasculature in normal Beagles and Beagles with inherited primary open-angle glaucoma. Vet Ophthalmol 1999, 2(2):97-105.
106. Hayreh S.S. The ophthalmic artery: III. Branches. Br J Ophthalmol 1962, 46(4):212-247.
107. Brooks D.E., Samuelson D.A., Gelatt K.N., et al. Scanning electron microscopy of corrosion casts of the optic nerve microcirculation in dogs. Am J Vet Res 1989, 50(6):908-914.
108. Mayordomo-Febrer A., Lopez-Murcia M., Morales-Tatay J.M., et al. Metabolomics of the aqueous humor in the rat glaucoma model induced by a series of intracamerular sodium hyaluronate injection. Exp Eye Res 2015, 131:84-92.
109. Osborne N.N. Pathogenesis of ganglion "cell death" in glaucoma and neuroprotection: focus on ganglion cell axonal mitochondria. Prog Brain Res 2008, 173:339-352.
110. Lin W.J., Kuang H.Y. Oxidative stress induces autophagy in response to multiple noxious stimuli in retinal ganglion cells. Autophagy 2014, 10(10):1692-1701.
111. Anderson D.R., Hendrickson A. Effect of intraocular pressure on rapid axoplasmic transport in monkey optic nerve. Invest Ophthalmol 1974, 13(10):771-783.
112. Cui H., Kong Y., Zhang H. Oxidative stress, mitochondrial dysfunction, and aging. J Signal Transduct 2012, 2012:646354.
113. Osborne N.N., Alvarez C.N., del Olmo Aguado S. Targeting mitochondrial dysfunction as in aging and glaucoma. Drug Discov Today 2014, 19(10):1613-1622.
114. Boveris A., Navarro A. Brain mitochondrial dysfunction in aging. IUBMB Life 2008, 60(5):308-314.
115. Malinin N.L., West X.Z., Byzova T.V. Oxidation as "the stress of life". Aging (Albany NY) 2011, 3(9):906-910.
116. Chrysostomou V., Rezania F., Trounce I.A., et al. Oxidative stress and mitochondrial dysfunction in glaucoma. Curr Opin Pharmacol 2013, 13(1):12-15.
117. El Assar M., Angulo J., Rodriguez-Manas L. Oxidative stress and vascular inflammation in aging. Free Radic Biol Med 2013, 65:380-401.
118. Wang J.Y., Wen L.L., Huang Y.N., et al. Dual effects of antioxidants in neurodegeneration: direct neuroprotection against oxidative stress and indirect protection via suppression of glia-mediated inflammation. Curr Pharm Des 2006, 12(27):3521-3533.
119. Chung H.Y., Sung B., Jung K.J., et al. The molecular inflammatory process in aging. Antioxid Redox Signal 2006, 8(3-4):572-581.
120. Haefliger I.O., Dettmann E., Liu R., et al. Potential role of nitric oxide and endothelin in the pathogenesis of glaucoma. Surv Ophthalmol 1999, 43(Suppl 1):S51-58.
121. Chen T., Gionfriddo J.R., Tai P.Y., et al. Oxidative stress increases in retinas of dogs in acute glaucoma but not in chronic glaucoma. Vet Ophthalmol 2015, 18(4):261-270.
122. Hernandez M.R., Miao H., Lukas T. Astrocytes in glaucomatous optic neuropathy. Prog Brain Res 2008, 173:353-373.
123. Waniewski R.A., Martin D.L. Exogenous glutamate is metabolized to glutamine and exported by rat primary astrocyte cultures. J Neurochem 1986, 47(1):304-313.
124. Goss J.R., O'Malley M.E., Zou L., et al. Astrocytes are the major source of nerve growth factor upregulation following traumatic brain injury in the rat. Exp Neurol 1998, 149(2):301-309.
125. Neumann C., Yu A., Welge-Lussen U., et al. The effect of TGF-beta2 on elastin, type VI collagen, and components of the proteolytic degradation system in human optic nerve astrocytes. Invest Ophthalmol Vis Sci 2008, 49(4):1464-1472.
126. Pena J.D., Netland P.A., Vidal I., et al. Elastosis of the lamina cribrosa in glaucomatous optic neuropathy. Exp Eye Res 1998, 67(5):517-524.
127. Zode G.S., Sethi A., Brun-Zinkernagel A.M., et al. Transforming growth factor-beta2 increases extracellular matrix proteins in optic nerve head cells via activation of the Smad signaling pathway. Mol Vis 2011, 17:1745-1758.
128. Yafai Y., Iandiev I., Lange J., et al. Muller glial cells inhibit proliferation of retinal endothelial cells via TGF-beta2 and Smad signaling. Glia 2014, 62(9):1476-1485.
129. Perry V.H., Nicoll J.A., Holmes C. Microglia in neurodegenerative disease. Nat Rev Neurol 2010, 6(4):193-201.
130. Neufeld A.H. Microglia in the optic nerve head and the region of parapapillary chorioretinal atrophy in glaucoma. Arch Ophthalmol 1999, 117(8):1050-1056.
131. Agarwal R., Agarwal P. Glaucomatous neurodegeneration: an eye on tumor necrosis factor-alpha. Indian J Ophthalmol 2012, 60(4):255-261.
132. Shen Y., Liu X.L., Yang X.L. N-methyl-D-aspartate receptors in the retina. Mol Neurobiol 2006, 34(3):163-179.
133. Lucas D.R., Newhouse J.P. The toxic effect of sodium L-glutamate on the inner layers of the retina. AMA Arch Ophthalmol 1957, 58(2):193-201.
134. Vorwerk C.K., Gorla M.S., Dreyer E.B. An experimental basis for implicating excitotoxicity in glaucomatous optic neuropathy. Surv Ophthalmol 1999, 43(Suppl 1):S142-150.
135. Dreyer E.B., Zurakowski D., Schumer R.A., et al. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch Ophthalmol 1996, 114(3):299-305.
136. McIlnay T.R., Gionfriddo J.R., Dubielzig R.R., et al. Evaluation of glutamate loss from damaged retinal cells of dogs with primary glaucoma. Am J Vet Res 2004, 65(6):776-786.
137. Brooks D.E., Garcia G.A., Dreyer E.B., et al. Vitreous body glutamate concentration in dogs with glaucoma. Am J Vet Res 1997, 58(8):864-867.
138. Siliprandi R., Canella R., Carmignoto G., et al. N-methyl-D-aspartate-induced neurotoxicity in the adult rat retina. Vis Neurosci 1992, 8(6):567-573.
139. Kemp J.A., McKernan R.M. NMDA receptor pathways as drug targets. Nat Neurosci 2002, 5(Suppl):1039-1042.
140. Madl J.E., McIlnay T.R., Powell C.C., et al. Depletion of taurine and glutamate from damaged photoreceptors in the retinas of dogs with primary glaucoma. Am J Vet Res 2005, 66(5):791-799.
141. Kwon Y.H., Rickman D.W., Baruah S., et al. Vitreous and retinal amino acid concentrations in experimental central retinal artery occlusion in the primate. Eye 2005, 19(4):455-463.
142. Ullian E.M., Barkis W.B., Chen S., et al. Invulnerability of retinal ganglion cells to NMDA excitotoxicity. Mol Cell Neurosci 2004, 26(4):544-557.
143. Lotery A.J. Glutamate excitotoxicity in glaucoma: truth or fiction?. Eye 2005, 19(4):369-370.
144. Findings of scientific misconduct. In: Services DoHH, editor. Available at: Accessed July 25, 2015. http://grants.nih.gov/grants/guide/notice-files/NOT-OD-01-006.html.
145. Dalton R. Private investigations. Nature 2001, 411(6834):129-130.
146. Olmos G., Llado J. Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity. Mediators Inflamm 2014, 2014:861231.
147. Wax M.B., Tezel G. Immunoregulation of retinal ganglion cell fate in glaucoma. Exp Eye Res 2009, 88(4):825-830.
148. Grus F.H., Joachim S.C., Wuenschig D., et al. Autoimmunity and glaucoma. J Glaucoma 2008, 17(1):79-84.
149. Yang X., Luo C., Cai J., et al. Neurodegenerative and inflammatory pathway components linked to TNF-alpha/TNFR1 signaling in the glaucomatous human retina. Invest Ophthalmol Vis Sci 2011, 52(11):8442-8454.
150. Maggio M., Guralnik J.M., Longo D.L., et al. Interleukin-6 in aging and chronic disease: a magnificent pathway. J Gerontol A Biol Sci Med Sci 2006, 61(6):575-584.
151. Xu H., Chen M., Forrester J.V. Para-inflammation in the aging retina. Prog Retin Eye Res 2009, 28(5):348-368.
152. Keller K.E., Aga M., Bradley J.M., et al. Extracellular matrix turnover and outflow resistance. Exp Eye Res 2009, 88(4):676-682.
153. Ueda J., Wentz-Hunter K., Yue B.Y. Distribution of myocilin and extracellular matrix components in the juxtacanalicular tissue of human eyes. Invest Ophthalmol Vis Sci 2002, 43(4):1068-1076.
154. Tamm E.R. Myocilin and glaucoma: facts and ideas. Prog Retin Eye Res 2002, 21(4):395-428.
155. Hart H., Samuelson D.A., Tajwar H., et al. Immunolocalization of myocilin protein in the anterior eye of normal and primary open-angle glaucomatous dogs. Vet Ophthalmol 2007, 10(Suppl 1):28-37.
156. Mackay E.O., Kallberg M.E., Gelatt K.N. Aqueous humor myocilin protein levels in normal, genetic carriers, and glaucoma Beagles. Vet Ophthalmol 2008, 11(3):177-185.
157. MacKay E.O., Kallberg M.E., Barrie K.P., et al. Myocilin protein levels in the aqueous humor of the glaucomas in selected canine breeds. Vet Ophthalmol 2008, 11(4):234-241.
158. Tripathi B.J., Tripathi R.C., Chen J., et al. Trabecular cell expression of fibronectin and MMP-3 is modulated by aqueous humor growth factors. Exp Eye Res 2004, 78(3):653-660.
159. Pizzirani S, Desai SJ, Pirie CG, et al. Age related changes in the anterior segment of the eye in normal dogs. Paper presented at: 41st Annual Meeting of the American College of Veterinary Ophthalmologists. San Diego, CA, October 6-9, 2010.
160. Oppenheim J.J., Yang D. Alarmins: chemotactic activators of immune responses. Curr Opin Immunol 2005, 17(4):359-365.
161. Cruise L.J., McClure R. Posterior pathway for aqueous humor drainage in the dog. Am J Vet Res 1981, 42(6):992-995.
162. Watson P., Grierson I., Hitchings R.A., et al. Pathological dilemmas in the outflow system in primary open-angle glaucoma - Discussion. Acta Ophthalmol Scand 1997, 75:13-14.
163. Sethi A., Mao W., Wordinger R.J., et al. Transforming growth factor-beta induces extracellular matrix protein cross-linking lysyl oxidase (LOX) genes in human trabecular meshwork cells. Invest Ophthalmol Vis Sci 2011, 52(8):5240-5250.
164. Hogg P., Calthorpe M., Ward S., et al. Migration of cultured bovine trabecular meshwork cells to aqueous humor and constituents. Invest Ophthalmol Vis Sci 1995, 36(12):2449-2460.
165. Hasegawa M., Sato S., Takehara K. Augmented production of transforming growth factor-beta by cultured peripheral blood mononuclear cells from patients with systemic sclerosis. Arch Dermatol Res 2004, 296(2):89-93.
166. Rhee D.J., Haddadin R.I., Kang M.H., et al. Matricellular proteins in the trabecular meshwork. Exp Eye Res 2009, 88(4):694-703.
167. Yehualaeshet T., O'Connor R., Green-Johnson J., et al. Activation of rat alveolar macrophage-derived latent transforming growth factor beta-1 by plasmin requires interaction with thrombospondin-1 and its cell surface receptor, CD36. Am J Pathol 1999, 155(3):841-851.
168. Davis G.E., Pintar Allen K.A., Salazar R., et al. Matrix metalloproteinase-1 and -9 activation by plasmin regulates a novel endothelial cell-mediated mechanism of collagen gel contraction and capillary tube regression in three-dimensional collagen matrices. J Cell Sci 2001, 114(Pt 5):917-930.
169. Fuchshofer R., Welge-Lussen U., Lütjen-Drecoll E. The effect of TGF-β2 on human trabecular meshwork extracellular proteolytic system. Exp Eye Res 2003, 77(6):757-765.
170. Mantovani A. Macrophage diversity and polarization: in vivo veritas. Blood 2006, 108(2):408-409.
171. Baatz H., Puchta J., Reszka R., et al. Macrophage depletion prevents leukocyte adhesion and disease induction in experimental melanin-protein induced uveitis. Exp Eye Res 2001, 73(1):101-109.
172. Parameswaran N., Patial S. Tumor necrosis factor-alpha signaling in macrophages. Crit Rev Eukaryot Gene Expr 2010, 20(2):87-103.
173. Merry H.E., Phelan P., Doaks M., et al. Functional roles of tumor necrosis factor-alpha and interleukin 1-Beta in hypoxia and reoxygenation. Ann Thorac Surg 2015, 99(4):1200-1205.
174. Perry R.T., Collins J.S., Wiener H., et al. The role of TNF and its receptors in Alzheimer's disease. Neurobiol Aging 2001, 22(6):873-883.
175. Nagatsu T., Sawada M. Inflammatory process in Parkinson's disease: role for cytokines. Curr Pharm Des 2005, 11(8):999-1016.
176. Tezel G., Li L.Y., Patil R.V., et al. TNF-alpha and TNF-alpha receptor-1 in the retina of normal and glaucomatous eyes. Invest Ophthalmol Vis Sci 2001, 42(8):1787-1794.
177. Sawada H., Fukuchi T., Tanaka T., et al. Tumor necrosis factor-alpha concentrations in the aqueous humor of patients with glaucoma. Invest Ophthalmol Vis Sci 2010, 51(2):903-906.
178. Durieux P., Etchepareborde S., Fritz D., et al. Tumor necrosis factor-alpha concentration in the aqueous humor of healthy and diseased dogs: a preliminary pilot study. J Fr Ophtalmol 2015, 38(4):288-294.
179. Nakazawa T., Nakazawa C., Matsubara A., et al. Tumor necrosis factor-alpha mediates oligodendrocyte death and delayed retinal ganglion cell loss in a mouse model of glaucoma. J Neurosci 2006, 26(49):12633-12641.
180. Tezel G. TNF-alpha signaling in glaucomatous neurodegeneration. Prog Brain Res 2008, 173:409-421.
181. Gregory M.S., Hackett C.G., Abernathy E.F., et al. Opposing roles for membrane bound and soluble Fas ligand in glaucoma-associated retinal ganglion cell death. PLoS One 2011, 6(3):e17659.